Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.

Blood - 15 Apr 2008

Tiedt Ralph, Hao-Shen Hui, Sobas Marta A, Looser Renate, Dirnhofer Stephan, Schwaller Jürg, Skoda Radek C

Abstract excerpt

An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPDs). Several phenotypic manifestations (polycythemia vera [PV], essential thrombocythemia [ET], and primary myelofibrosis) can be associated with the same mutation. We generated JAK2-V617F transgenic mice using a human JAK2 gene with the sequences encoding the kinase domain placed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colony-Forming Units Assay
Share to Granulocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hyperplasia

Share to Integrases

Share to Megakaryocytes

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 18160670
DOI: 10.1182/blood-2007-08-107748

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.PMID 18160670Read ↗

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice.Semantic proximity Read ↗

Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera–like diseaseSemantic proximity Read ↗

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.Semantic proximity Read ↗

Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in miceSemantic proximity Read ↗

A role for JAK2 mutations in myeloproliferative diseases.Semantic proximity Read ↗

Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative DisordersSemantic proximity Read ↗

Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.Semantic proximity Read ↗

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemiaSemantic proximity Read ↗

Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Semantic proximity Read ↗

Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.Semantic proximity Read ↗

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.Semantic proximity Read ↗

JAK-2 mutations and their relevance to myeloproliferative diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.